MSD’s investment in Meath will accelerate the time it takes to bring medicine to market.

Pharmaceutical giant MSD plans to build a new manufacturing facility at the company’s newly acquired Dunboyne Biologics campus in Co Meath.

The new facility is expected to create an estimated 140 new jobs by 2025 and will support an innovative new approach to developing and launching MSD’s future biologics medicines. Additionally, the existing MSD Dunboyne Biologics facility expect to hire approximately 100 new employees within the coming year.  

“The 240 additional jobs being created at the Dunboyne Biologics Camp will be a substantial boost to the regional economy”

An Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, described the new jobs as a “really welcome boost for Meath.”

Co-locating this new facility beside an existing plant will support greater innovation and collaboration between MSD’s research and manufacturing teams, which will significantly accelerate the time it takes to bring a medicine to market benefiting patients world-wide.

Planning and design of the facility will commence immediately, with the aim of completing construction and commencing operations in 2023.

Global impact

“This is an exciting new direction for MSD and will see our manufacturing and medical research colleagues working collaboratively and flexibly to speed up the process of bringing the medicines of tomorrow to the patients that need them as quickly as possible,” explained Sanat Chattopadhyay, Executive Vice President & President, Manufacturing Division, MSD.

“By co-locating the new facility alongside our existing operations in Dunboyne, we can accelerate the commercialisation process, reduce lead times significantly and build the ideal environment for developing new technologies and talent.”

MSD Ireland is one of the country’s leading healthcare companies, having first established here over 50 years ago.  MSD currently employs approximately 2,700 employees, across our six sites in Ballydine, Co Tipperary, Brinny, Co Cork, Carlow, Dunboyne, Co. Meath and Dublin and, in addition, operate substantial Human Health and Animal Health businesses.

“This expansion will offer a truly unique approach to manufacturing, ensuring that Dunboyne Biologics is at the cutting edge of pharmaceutical manufacturing and offering our team incredible career opportunities and experience,” explained Eva Gallagher, plant manager at MSD Dunboyne Biologics.

“It’s a really exciting time for our site but also our MSD Ireland colleagues, positioning us at the very heart of MSD’s future.”

MSD’s Irish sites manufacture approximately half of MSD’s top twenty products, saving and enhancing lives in over sixty countries around the world.

The news was welcomed by IDA Ireland CEO Martin Shanahan who said: “This expansion positions the Dunboyne Biologics Camp to become an integral part of the company’s global operations as it prepares to meet increasing global demand for its products.  It shows real commitment to, and confidence in Co Meath and the wider Mid-East Region, and in Ireland. MSD is a significant and valued investor in Ireland since it first established operations here more than 50 years ago,” said Shanahan.

“The 240 additional jobs being created at the Dunboyne Biologics Camp will be a substantial boost to the regional economy.”

By John Kennedy (john.kennedy3@boi.com)

Published: 10 December 2020

Recommended